Beli & Jual Brigit Biofarmaka Teknologi Tbk. - OBAT Hari Ini
Quarterly
Yearly
Income Statement
Revenue
Net Profit
Net Loss
Profit margin %
Q4
’24
Q1
’25
Q2
’25
Q3
’25
Q4
’25
| Item | Q4 2025 | Y/Y Change |
| Revenue | Rp160,12 M | +32.74% |
| Cost of Revenue | Rp97,26 M | +54.99% |
| Gross Profit | Rp62,86 M | +8.61% |
| General Expenses, Depreciation, Interest | Rp30,38 M | +54.28% |
| Operating Profit | Rp32,47 M | -14.95% |
| Other Income | Rp380,52 jt | -71.74% |
| EBT | Rp32,85 M | -16.89% |
| Taxes | -Rp7,27 M | -180.52% |
| Net Income | Rp22,64 M | -23.05% |
Balance Sheet
Assets
Liabilities
Debt to Asset %
Q4
’24
Q1
’25
Q2
’25
Q3
’25
Q4
’25
| Item | Q4 2025 | Y/Y Change |
| Total Assets | Rp131 M | +98.83% |
| Total Liabilities | Rp20,99 M | -5.44% |
| Total Equity | Rp106,93 M | +153.02% |
| Total Liabilities & Total Equity | Rp127,92 M | +98.46% |
Cash Flow
Operating
Investing
Finance
Net CF
Q4
’24
Q1
’25
Q2
’25
Q3
’25
Q4
’25
| Item | Q4 2025 | Y/Y Change |
| CF from Operations | Rp23,72 M | +83.02% |
| CF from Investment | Rp34,73 M | +292.38% |
| CF from Financing | Rp33,95 M | -2064.33% |
| Net Cash Flow | Rp22,95 M | +862.7% |